The top-cited paper in cluster 1 described a phase III trial demonstrating survival benefit in patients undergoing anti-CTLA4 therapy (96) which has been cited by a preclinical study in sub-cluster 1-3 that revealed the mechanism of tumor-specific mutant antigen, and the target of checkpoint blockade therapy, thus proposing personalized cancer-specific vaccines (97). This evidence concerns the gene CTLA4 and cancer.